Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial,Journal of the American Academy of Dermatology

当前位置： X-MOL 学术 › J. Am. Acad. Dermatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Journal of the American Academy of Dermatology ( IF 12.8 ) Pub Date : 2024-10-17 , DOI: 10.1016/j.jaad.2024.09.064
Melissa Piliang MD, Charles Lynde MD, Brett King MD PhD, Paradi Mirmirani MD, Rodney Sinclair MBBS MD, Maryanne Senna MD, Seth Forman MD, Lindsey Bordone MD, Pablo De La Cueva Dobao MD, Robert Wolk MD PhD, Samuel H. Zwillich MD, Helen Tran PharmD, Dalia Wajsbrot MSc, Haytham Mohamed Ahmed BSc, Liza Takiya PharmD

Few treatments for alopecia areata have demonstrated sustained efficacy.

中文翻译：